Surrozen, Inc./DE (SRZN) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$17.15

From 52W high−51.51%

Volume190168.00

Market cap$194.52M

P/E (TTM)—

P/S (TTM)16.9x

Div yield—

Key dataSep 18, 2026

Open

$17.15

From 52W high

−51.51%

Volume

190168.00

Market cap

$194.52M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.3x

P/E (TTM)

—

RSI (14)

24.1

MomentumView details →

1D Return

−2.30%

YTD Return

−24.54%

SummaryUpdated Jun 1, 2026

Surrozen, Inc. (NASDAQ:SRZN) is a biotechnology company founded in 2015 and headquartered in South San Francisco, California. The company went public in January 2021 and focuses on discovering and developing drug candidates that selectively modulate the Wnt signaling pathway for tissue repair and regeneration. Surrozen represents a specialized approach to regenerative medicine, targeting various organ systems including the liver, intestines, retina, and other tissues through its proprietary antibody-based therapeutics.

Ask drillr about Surrozen, Inc./DE →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.3x

EV/Sales

8.6x

P/S (TTM)

16.9x

P/B (TTM)

−0.9x

ProfitabilityView details →

Gross Margin

99.44%

Net Margin

−2885.33%

EBITDA Margin

−2883.84%

ROE (TTM)

151.89%

ROA (TTM)

−287.29%

Asset Turnover

0.10x

GrowthView details →

Revenue YoY

−8.79%

EPS YoY

—

FCF YoY

−86.81%

Revenue CAGR 3Y

−34.72%

EPS CAGR 3Y

−49.38%

EBITDA YoY

—

MomentumView details →

1D Return

−2.30%

YTD Return

−24.54%

1Y Return

+38.87%

RSI (14)

24.1

vs 50D SMA

−21.85%

vs 200D SMA

−29.68%

Capital & dividendView details →

Debt/Equity

−0.03x

Current Ratio

12.14x

Quick Ratio

12.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.41

EPS Surprise

68.22%

Beats (12Q)

5/12

Next Q EPS Est

−$1.10

Avg Surprise (4Q)

−202.93%

Rev Surprise

970.09%

Financials snapshotView financials →

Revenue (TTM)

11.51M

Net Income (TTM)

−332.13M

Op. CF (TTM)

−34.76M

Next earningsNov 6, 2026 →

Latest newsMore news →

Surrozen submitted an Investigational New Drug application to the U.S. Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema.12d ago

Similar companies

Sol-Gel Technologies Ltd.SLGL Oramed Pharmaceuticals Inc.ORMP PepGen Inc.PEPG Acumen Pharmaceuticals, Inc.ABOS AN2 Therapeutics, Inc.ANTX Voyager Therapeutics, Inc.VYGR Find similar companies →

Latest newsMore news →